Another CB1 inverse agonist compound (which still calls for investigation but has shown promising results for the treatment of obesity while maintaining low plasma/brain concentration) is Compound2p, whose administration showed enhanced glucose absorption in obese animals [170]. Here, CNR1 is linked to obesity disorder.